Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumors: Literature-Based Insights

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a rare, highly aggressive malignancy, first described in 1989 and largely affecting children and young adults. Characterized by the EWS-WT1 fusion protein, IADSRCT has an estimated 5-year overall survival rate of only 15–30%, reflecting both its invasive nature and the lack of standardized, effective therapies. The therapeutic landscape has remained limited to combinations of surgical resection, intensive chemotherapy, and radiotherapy, with poor outcomes and high relapse rates. Against this backdrop, the referenced case study (Chen and Feng, 2019) investigates whether targeting angiogenesis with anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor (TKI), could represent a viable strategy in this challenging context.

Key Innovation from the Reference Study

The reference report is the first to document the clinical application of anlotinib in IADSRCT. Anlotinib’s mechanism—concurrent inhibition of VEGFR1–3, FGFR1–4, PDGFRα/β, c-Kit, and Met—positions it as a broad-spectrum angiogenesis and tumor growth inhibitor. This case demonstrates that multi-pathway inhibition, via a single oral TKI, can yield measurable clinical responses in a tumor type previously resistant to most modalities. The innovation is not only in the agent’s multitargeted action but also in showing practical, real-world feasibility for maintenance therapy in a patient who had exhausted standard options.

Methods and Experimental Design Insights

While the core evidence arises from a single-patient case report, the study’s design integrates a robust clinical, radiological, and pathological assessment. The 38-year-old male patient underwent laparoscopic resection of both the primary intra-abdominal and anterior abdominal wall nodules. Histopathology confirmed IADSRCT, and immunohistochemistry supported the diagnosis with positivity for AE1/AE3, desmin, NSE, Ck7, CD34, CD99, and partial positivity for CD56, GATA3, and Syn.

Following diagnosis, the patient received six cycles of adjuvant chemotherapy. Upon detection of metastatic lymphadenopathy on CT, anlotinib was initiated as salvage and then maintenance therapy. Treatment response was assessed through serial imaging, clinical monitoring, and laboratory evaluations. Importantly, toxicity was systematically documented, providing early safety insights for this rare context.

Core Findings and Why They Matter

After four cycles of anlotinib, the patient’s lymph node metastases regressed significantly, as measured by CT scans. The patient continued on anlotinib maintenance and remained in good clinical condition throughout the observation period. Reported side effects were limited to elevated triglycerides and fatigue, both of which were manageable and did not require discontinuation.

These findings support several key points:

• Demonstrated efficacy in a chemo-refractory setting: The observed reduction in metastatic burden indicates that anlotinib’s inhibition of multiple receptor tyrosine kinases—including VEGFR, PDGFR, and FGFR pathways—can counteract angiogenesis and tumor progression even after conventional cytotoxic therapy fails.
• Manageable toxicity profile: Despite its multi-targeted action, anlotinib did not produce dose-limiting toxicities in this case, echoing its relatively favorable safety parameters reported in broader oncology studies.
• Support for anti-angiogenic strategies in rare sarcomas: The case encourages further investigation of anti-angiogenic small molecules in IADSRCT and possibly similar soft tissue sarcomas, expanding the paradigm beyond traditional chemotherapy.

The clinical rationale is consistent with preclinical and translational data showing that anlotinib effectively inhibits endothelial cell migration and capillary-like tube formation—hallmarks of angiogenesis—at nanomolar concentrations in vitro, while blocking the ERK signaling pathway downstream of its targets (product information).

Comparison with Existing Internal Articles

Several recent publications have explored the mechanistic and practical aspects of anlotinib hydrochloride in angiogenesis and cancer research. For example, the review “Anlotinib Hydrochloride: Redefining Angiogenesis Inhibition” provides a mechanistic deep dive into anlotinib’s inhibition of VEGFR2, PDGFRβ, and FGFR1, emphasizing its nanomolar potency and suitability for endothelial cell migration inhibition and capillary tube formation assays. Similarly, “Optimizing Endothelial Assays with Anlotinib” addresses laboratory workflow optimization, highlighting the compound’s low cytotoxicity and robust reproducibility in functional assays.

The case report by Chen and Feng bridges the gap between these preclinical insights and clinical application. Where internal resources focus on assay optimization, selectivity, and quantitative outcomes in vitro, the clinical case extends these findings to actual patient care, demonstrating real-world translational potential. Notably, the efficacy observed in IADSRCT aligns with anlotinib’s validated ability to block VEGF/PDGF-BB/FGF-2-induced endothelial processes—mechanisms fundamental to tumor vascularization and metastatic spread.

Limitations and Transferability

It is essential to recognize that this study is a single-case report, inherently limited in generalizability. The lack of a control group, the potential influence of prior therapies, and the short-term follow-up restrict conclusions about long-term efficacy and safety. Furthermore, IADSRCT is a rare tumor entity, and patient heterogeneity may influence response to targeted agents.

Nevertheless, the clinical response observed provides a critical proof-of-concept, justifying further investigation in larger cohorts or basket trials. The case also underscores the practical transferability of in vitro findings to the clinic, suggesting that well-characterized multi-target TKIs can be rationally repositioned for rare and refractory malignancies, provided their pharmacokinetic and safety profiles are suitable.

Protocol Parameters

• Patient selection: Ideal for IADSRCT with confirmed EWS-WT1 translocation and evidence of progressive/metastatic disease post-chemotherapy.
• Anlotinib initiation: Initiate upon evidence of relapse or new metastases, with baseline lipid panel and clinical monitoring.
• Dosing and schedule: Follow established oral dosing regimens used in solid tumor trials; adjust based on toxicity and patient tolerance.
• Response assessment: Serial CT imaging every 2–3 cycles; monitor for regression of lymphadenopathy and new lesions.
• Toxicity management: Regular monitoring for hyperlipidemia, fatigue, and other adverse effects; dose modifications as clinically indicated.
• Preclinical functional assays: For laboratory validation, use EA.hy 926 or similar human endothelial cell lines; assess VEGF/PDGF-BB/FGF-2-induced migration and tube formation at nanomolar concentrations (product reference).

Research Support Resources

Researchers aiming to translate these findings to laboratory or preclinical models can utilize Anlotinib hydrochloride (SKU C8688), a well-characterized multi-target tyrosine kinase inhibitor with validated activity in endothelial and cancer cell assays. APExBIO provides detailed product specifications and workflow guidance to support functional studies of angiogenesis, ERK signaling pathway inhibition, and related endpoints. For further protocol optimization and mechanistic insights, internal reviews such as “Anlotinib Hydrochloride: Advanced Multi-Target TKI in Angiogenesis Assays” offer evidence-based recommendations tailored to cancer research workflows.